Question 1

What is C-peptide, and why is it in your blood?

Accepted Answer

The pancreas does not build insulin in one piece. It builds a longer molecule called proinsulin and then cuts it, and C-peptide is the offcut. A 1982 review in Diabetes Care states it plainly: C-peptide is a polypeptide originating from proinsulin after its cleavage in the B-cell. It is secreted equimolarly with the other cleavage product, insulin, into the portal circulation, which is the blood running from the gut to the liver. Equimolar means one piece of C-peptide released for every molecule of insulin. From there the two part company. Only a minimal fraction of C-peptide is extracted by the liver; it is supposed to be mainly removed by the kidney, and a small, constant proportion is excreted in the urine. That difference in handling is why a C-peptide figure behaves unlike an insulin figure.

Question 2

What is a C-peptide blood test used for?

Accepted Answer

Two jobs, mainly, and the 1982 review lists both. Clinical applications of C-peptide include differentiating between endogenous and exogenous hyperinsulinism and establishing the need of insulin therapy in diabetic patients already treated with insulin. Endogenous means made by the body, exogenous means it arrived from outside, and hyperinsulinism means too much insulin about. Insulin drawn from a vial carries no C-peptide with it, so the reading separates what a pancreas made from what a syringe delivered. Both halves are cut from the same parent molecule, and only one of them is in the vial. The second job is sorting out which kind of diabetes somebody has. A biomarker is a number read off a blood sample that stands in for something harder to see. A 2022 review calls C-peptide a valuable clinical biomarker, mainly in autoimmune diabetes and especially in adult-onset diabetes. Estimates of insulin secretory capacity are useful to inform clinical practice, helping to classify types of diabetes, which in plain terms means working out how much insulin a person can still make. A 1990 review states the oldest use in one line: measurement of C-peptide may help to decide when insulin therapy is required.

Question 3

How is the sample taken and measured?

Accepted Answer

From blood, usually, and sometimes from urine. C-peptide is measured in serum and urine by radioimmunoassay, the 1982 review records, and that paper is candid about what can go wrong inside the method. The major sources of error of the assay are related to standard, tracer, antiserum specificity and reactivity with proinsulin, and to degradation of C-peptide. Some tests read the blood at rest and others prod the pancreas first. Many secretagogues are used to evaluate the B-cell function, of which glucagon is the most simple, a secretagogue being anything given to make a gland secrete. Research runs the same trick with food. Trials in type 1 diabetes have grouped people by baseline stimulated peak C-peptide concentration (mixed-meal tolerance test [MMTT]), and a 2025 islet study used detection of serum C-peptide during a 4-hour mixed-meal tolerance test. A resting figure and a stimulated figure are not the same measurement.

Question 4

Is there a normal range for C-peptide?

Accepted Answer

There is no single range across this material, and the reason matters more than any figure. Problems remain in the standardization of the assay for C-peptide, raising concerns about comparability of measurements between different laboratories, the 2022 review states. Two laboratories can hand back different numbers for the same blood. The units differ as well. An international panel on latent autoimmune diabetes worked in nanomoles per litre, treating C-peptide values ≥0.3 and ≤0.7 nmol/L as a gray area and C-peptide values >0.7 nmol/L as something else again. A 2021 real-world study instead selected type 2 DM patients with C-peptide values >1 ng/ml, and a 2022 trial grouped people by a C-peptide level of ≥0.6 ng/mL. Those are entry criteria written for one study rather than a reference range, and a number means little without its units and its laboratory beside it.

Question 5

What does a high C-peptide reading mean?

Accepted Answer

A high reading means a pancreas releasing plenty of insulin, and the company it usually keeps is insulin resistance. A 2020 review describes a decline in pancreatic beta-cell function as a key contributing factor to progression of T2D, and adds that a significant proportion of beta-cell secretory capacity is thought to be lost well before the diagnosis of T2D is made. Output can run high for years before that decline shows. The 2022 review is blunt about how much a high figure can carry in that setting, since the lack of robust evidence about the clinical utility of C-peptide measurement in type 2 diabetes, where insulin resistance is a major confounder, limits its use in such cases. High can also mean something was given. In a 2026 phase 1 trial of a new weight-loss compound in men with overweight or obesity, metabolic improvements included lower fasting glucose, triglycerides, uric acid and elevated insulin/C-peptide.

Question 6

What does a low C-peptide reading mean?

Accepted Answer

A low reading means little insulin is being made, and the clearest version of that is type 1 diabetes. In a 2025 trial of a stem-cell islet therapy, C-peptide was undetectable at baseline in all 14 participants. A 2019 transplant series split people the same way, between patients without measureable C-peptide (insulin-dependent type 1 diabetes mellitus) and patients with detectable pretransplant C-peptide (insulin-dependent type 2 diabetes mellitus). A low reading can also arrive suddenly. A 2017 case report describes a 63-year-old woman admitted with diabetic ketoacidosis after a cancer immunotherapy, and on admission, the C-peptide level was low, and the HbA1c concentration was 50 mmol/l indicating a rapid onset of the disease. One figure told that team how fast her pancreas had gone quiet, which is the sort of question a C-peptide reading answers well.

Question 7

Why measure C-peptide instead of insulin?

Accepted Answer

Three reasons, and all of them come from how a body handles the two molecules. First, insulin is stripped out heavily on its way through the liver, while only a minimal fraction of C-peptide is extracted by the liver, so the C-peptide figure tracks what the pancreas released rather than what survived the journey. Second, C-peptide secretion mirrors beta-cell function, so the reading stands in for how much working tissue is left. Third, an insulin assay cannot tell a body's own insulin from injected insulin, whereas clinical applications of C-peptide include differentiating between endogenous and exogenous hyperinsulinism. For anybody already using insulin, that third point is the reason the test exists at all. The 1990 review gives the working version: measurement of C-peptide may help to decide when insulin therapy is required.

Question 8

Is C-peptide the same as A1c?

Accepted Answer

No, and they answer different questions. A 1990 review sets the two side by side: measuring HbA1c permits assessment of the mean blood sugar value of the last 1 1/2-2 months, while measurement of C-peptide may help to decide when insulin therapy is required. A1c is a record of where blood sugar has been for weeks. C-peptide is a reading of what the pancreas can still do today. The two are often drawn from the same sample precisely because they do not overlap. A 2020 review shows them working together, reporting that significant beta-cell dysfunction is likely in individuals with certain clinical characteristics of T2D, such as long duration of disease, high glycated hemoglobin (≥9%), and/or long-term use of therapies that continuously stimulate the beta cell. A high A1c alongside a high C-peptide and a high A1c alongside almost none point in different directions.

Question 9

What can move a reading without the pancreas failing?

Accepted Answer

Several things do, and a number of them are medicines. In nine haemodialysis patients given ciclosporin for two weeks, second-phase insulin secretion decreased significantly (30%) following CsA treatment (P = 0.045). Calculation based on C-peptide concentrations gave the same results. Ciclosporin damps down the immune system, and haemodialysis does the work of failed kidneys. A 2022 crossover trial in 12 patients with obesity and type 2 diabetes found that glucagon, GLP-1 and C-peptide concentrations increased after sacubitril/valsartan, a heart medicine. A crossover trial gives each person both arms in turn, so every patient acts as their own comparison. A 2021 analysis of tirzepatide in 316 patients reported that proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased. Food shifts the reading too: in eighteen healthy men, glucose, insulin, C-peptide, glucagon, GLP-1, GIP, valine, leucine and isoleucine concentrations were measured after amino acids by mouth and by vein. Amino acids are the small parts protein is built from, and the last three on that list are three of them. Insulin from a vial pushes the reading the other way. In cholesterol-fed rabbits injected daily with human insulin, plasma C-peptide ran lower than in placebo rabbits. Those are things seen in trials of other compounds rather than levers for moving a number on purpose.

Question 10

How does the number guide decisions about insulin?

Accepted Answer

By bands, and the bands are written down. An international expert panel on latent autoimmune diabetes of adults, a slowly evolving form of autoimmune diabetes, wrote that within LADA, C-peptide values, proxy for β-cell function, drive therapeutic decisions, and set out three broad categories of random C-peptide levels. A proxy is a stand-in measure, and the beta cells are the ones that make insulin. Random here just means the blood was drawn without timing it to a meal. In ketosis-prone diabetes the number does a different job, because measurements of C-peptide levels are essential to predict remission and guide potential insulin withdrawal. Remission there means a person can come off insulin for a while. Insurance uses it as well, and not always to the patient's advantage. A 2025 trial notes that the Centers for Medicare & Medicaid Services (CMS) requires a low C-peptide level for insulin pump coverage unless the individual is β-cell autoantibody positive, which precludes coverage of automated insulin delivery (AID) systems for many people with type 2 diabetes. That same trial then found the benefit of AID is present with high and low C-peptide levels. So the rule and the result point in different directions.

Question 11

What does C-peptide show after an islet or cell transplant?

Accepted Answer

It is the readout that shows transplanted cells are alive and working. In a 2025 phase 1-2 study, detection of serum C-peptide during a 4-hour mixed-meal tolerance test was used to assess engraftment and islet function, and after the infusion all the participants had engraftment and islet function, as evidenced by the detection of C-peptide. Islets are the clusters in the pancreas that hold the insulin-making cells, and engraftment means they took hold and stayed alive. A 2021 study of implanted stem-cell-derived cells reported that patients had increased fasting C-peptide levels and increased glucose-responsive C-peptide levels. Glucose-responsive means the level went up when blood sugar did, which is what working cells do. In a 2025 case report of gene-edited donor cells placed in a man's forearm muscle, C-peptide measurements showed stable and glucose-responsive insulin secretion. Older islet work leaned on the same signal, and a 2015 review records that patients showed permanent C-peptide secretion, which facilitated glycemic control. In every one of those the reading is evidence about the graft rather than a benefit anybody felt.

Question 12

Does the reading track type 1 diabetes over time?

Accepted Answer

It is the standard yardstick for whether anything was preserved. In a 2013 randomised trial, patients treated with teplizumab had a reduced decline in C-peptide at 2 years versus control, a 75% improvement. A slower decline is not a gain, and it only means the fall was gentler than it would have been. In a 2021 phase 2 trial in 308 adults with recent-onset type 1 diabetes, the decrease in MMTT-stimulated C-peptide concentration from baseline to week 54 was significantly smaller with combination treatment, though the effects diminished upon treatment cessation. MMTT is the mixed-meal test, where a drink is given and the blood is sampled for hours after it. A 2026 real-world series followed 22 evaluable patients after low-dose antithymocyte globulin, where average mQR at 1 year was 0.072 and there were 15 responders (+mQR) and 7 nonresponders (-mQR). Older work shows the same yardstick measuring nothing at all: in a 1990 trial, fasting and glucagon-stimulated C-peptide levels were similar for the control and nicotinamide treated groups at the beginning and after 4 and 12 months. A yardstick that can show no change is the kind worth having.

Question 13

Does C-peptide do anything itself, or is it only a marker?

Accepted Answer

That question has swung twice. For years an assumption was made that C-peptide, a byproduct of insulin biosynthesis, possessed no appreciable physiologic role, a 2004 review recalls, before arguing that the time has come to re-evaluate that notion. A 2023 review goes further and calls C-peptide not only an indicator of pancreatic β-cell function, but also a biologically active peptide that can bind to cell membrane surface signaling molecules and activate downstream signaling pathways. Kidney work is the strongest version of the case, since in diabetic rodents, C-peptide reduces glomerular hyperfiltration and albuminuria, a 2017 review reports. Then the swing back. A 2021 review concludes that the concept of C-peptide as a hormone is presently not supported, while allowing that some of its bioactivities continue to influence our understanding. Activity in a dish and a job in a living body are different claims.

Question 14

Has C-peptide ever been given to patients?

Accepted Answer

Yes, inside research, and how that turned out is the reason this page is about a reading rather than about something to acquire. A 2017 review records that studies of C-peptide in animal models and in humans with type 1 diabetes all suggest a renoprotective effect for this peptide, and that in short-term studies of patients with type 1 diabetes, administration of C-peptide is also associated with a lowered hyperfiltration rate and reduced microalbuminuria. A 2004 review adds that short-term C-peptide infusion to type 1 diabetic patients restores normal Na+,K(+)-ATPase activity, an enzyme that shifts sodium and potassium across cell membranes. Then came the trials. A 2023 review states the outcome without decoration: results from clinical trials have been unsatisfactory. A 2021 review says the same thing in passing, noting that the peptide has turned out not to be important in diabetes care. No amount, schedule or route appears anywhere on this page, because what readers arrive holding is a laboratory figure.

Question 15

What does a single reading not establish?

Accepted Answer

Quite a lot, and this is the part worth carrying away. A reading records how much of something a body holds at one moment. It says nothing about what happened after anybody was given anything, and those two things are confused constantly. A 2026 analysis within a trial of 5,047 adults with type 2 diabetes found that treatment-associated changes in fasting glucagon, GGI, and fasting C-peptide were not associated with the primary metabolic outcome. A 2025 randomised trial reached a blunter version, concluding that requiring a low C-peptide level as a prerequisite for AID therapy is not warranted. In 205 newly diagnosed Chinese patients with type 1 diabetes, there were no significant differences in C-peptide and glycated hemoglobin between the antibody groups being compared. A figure can be real, repeatable and still fail to settle the question somebody brought to it.

C-peptide